CIBC Innovation Banking provided growth finance to InsightRX, a software startup based in San Francisco, CA that uses artificial intelligence (AI) and quantitative pharmacology.
The deal’s total value was not made public.
The money will be used by the business to increase operations and development initiatives.
“We are proud that InsightRX is leading the transition from the traditional ‘one-size-fits-all’ approach in drug dosing to a more individualized treatment paradigm that considers the unique characteristics of patient subgroups and the specific needs of each patient. This shift is not just pivotal for patient care but also for the introduction of new drugs to the market. To help us achieve our strategic vision of transforming patient care, we worked with CIBC for the necessary financing to accelerate our growth. CIBC showed intellectual curiosity about the intricacies of our business and were thoughtful in their approach.”
Sirj Goswami, CEO
Under the direction of CEO Sirj Goswami, InsightRX customizes dosage for sophisticated medications such as immunosuppressants, chemotherapeutic drugs, and antibiotics using patient-specific data and quantitative models. AI is also used by the organization to enable data scientists to analyze data from clinical trials, support trial design, comprehend dose-exposure-response correlations, and improve dosing plans for regulatory filings.
Thanks to its platform, which offers a personalized understanding of each patient’s reaction to therapy, doctors may more effectively introduce new medications into the market, enhance the efficacy of existing treatments, and directly benefit patients.
